tirzepatide ban update WADA just added (mounjaro) to the 2026 Monitoring Program Is Compounded Tirzepatide Banned? Latest

Pushing the Boundaries of GLP-1 Innovation Hanmi to Present Six Obesity Drug Studies at ADA 2025Hanmi Pharmaceutical to Unveil Six Research Updates on HM15275 and HM17321 at ADA 2025Phase 1 Results of Next-Generation Triple Agonist HM15275 to Be Unveiled for the First Time

GLP-1s and exercise don't have to feel overwhelming

94.1% completed the study and 78.6% remained on treatment at EOS

p=0.02) and 5% (95% CI 8%, 2%

GLP-1 receptor agonists like Ozempic may pose risks for patients with ulcerative colitis

Glucagon-like peptide 1 (GLP-1) receptor agonists are revolutionizing obesity and type 2 diabetes treatment, delivering remarkable weight loss outcomes